ARCT - NASDAQ

Arcturus Therapeutics Holdings Inc.

ARCT·NASDAQ

$7.60

+0.80%

HealthcareBiotechnology

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$216.02M

EPS-2.4000

P/E Ratio-3.17

Earnings Date08/10/2026

271.15M

Assets

-21%

3Y-40.0%

5Y-43.0%

10Y+426.0%

57.16M

Total Liabilities

-45%

3Y-68.0%

5Y-28.0%

10Y+1217.0%

213.99M

Total Equity

-11%

3Y-21.0%

5Y-46.0%

10Y+353.0%

Arcturus Therapeutics Holdings Inc. Funding & Solvency Profile

ARCT · NASDAQ

Current Assets

Cash & Cash Equivalents230.91M

Net Receivables5.56M

Inventory0.00

Other Current Assets4.97M

Total Current Assets241 M

Non-Current Assets

Property, Plant & Equipment27.82M

Goodwill & Intangible Assets0.00

Long-Term Investments1.89M

Other Non-Current Assets0.00

Total Non-Current Assets30 M

Total Assets

271.15M

Financial Health Analysis

Current Ratio

6.64x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.27x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

205 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

89% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Arcturus Therapeutics Holdings Inc. Balance Sheet

ARCT • NASDAQ

Arcturus Therapeutics Holdings Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	230.9M	237M	292M	391.9M	370.5M	462.9M	71.4M	36.7M	25M	2.3M	16.7M	2.2M	22.1M	97K	55K
Short-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	23.6M	47.9M	34M	19.5M	28M	0.0	517K
Cash & Short-Term Investments	230.9M	237M	292M	391.9M	370.5M	462.9M	71.4M	36.7M	48.6M	50.2M	50.7M	21.7M	50.1M	97K	572K
Net Receivables	5.6M	4M	32.1M	2.8M	3.4M	2.1M	2.2M	4.5M	480K	3.6M	328K	117K	46K	10K	93K
Accounts Receivables	5.6M	4M	32.1M	2.8M	3.4M	2.1M	2.2M	4.5M	480K	3.6M	0.0	0.0	0.0	10K	0.0
Other Receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	116K	117K	46K	0.0	93K
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5M	-521K	-116K	0.0	-46K	0.0	0.0
Prepaids	0.0	0.0	7.5M	0.0	5.1M	2.8M	758K	638K	1.1M	242K	1.1M	311K	18K	73K	2K
Other Current Assets	5M	65M	55M	8.7M	0.0	0.0	0.0	0.0	756K	111K	93K	0.0	0.0	0.0	0.0
Total Current Assets	241.4M	306M	386.6M	403.3M	379M	467.8M	74.3M	41.8M	50.9M	51.3M	52.3M	22.1M	50.2M	180K	667K
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	27.8M	36.2M	40.9M	45M	11.3M	8.6M	7.5M	2M	1M	240K	227K	97K	49K	18K	25K
Goodwill & Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-26.7M	0.0	0.0	0.0	0.0	0.0	0.0
Long-Term Investments	1.9M	0.0	1.9M	0.0	515K	0.0	263K	288K	107K	0.0	19M	0.0	0.0	3K	0.0
Tax Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	26.6M	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	0.0	1.9M	0.0	2.1M	2.1M	107K	107K	107K	107K	29K	110K	95K	57K	0.0	512K
Total Non-Current Assets	29.7M	38.1M	42.8M	47.1M	13.9M	8.7M	7.9M	2.4M	1.2M	269K	19.3M	192K	106K	21K	537K
Total Assets	271.1M	344.1M	429.4M	450.4M	392.8M	476.5M	82.1M	44.2M	52M	51.6M	71.7M	22.3M	50.3M	201K	1.2M
LIABILITIES
CURRENT LIABILITIES
Total Payables	4.2M	7.2M	5.9M	8.7M	10.1M	10.8M	5.8M	2.4M	1.8M	3.4M	57K	305K	47K	23K	124K
Accounts Payable	4.2M	7.2M	5.3M	7.4M	10.1M	10.8M	5.8M	2.4M	1.8M	3.4M	57K	305K	47K	23K	124K
Other Payables	0.0	0.0	641K	1.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accrued Expenses	0.0	19.5M	5.9M	13.5M	19.2M	11.2M	1.6M	1.6M	1.8M	692K	1.3M	2.1M	1.6M	83K	95K
Short Term Debt	4.2M	0.0	0.0	60.7M	22.5M	1.3M	0.0	0.0	0.0	133K	0.0	0.0	0.0	662K	0.0
Capital Lease Obligations (Current)	0.0	3.6M	4.3M	3.9M	1.5M	1.6M	827K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	0.0	641K	1.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	8.2M	21.9M	47.3M	36.1M	0.0	0.0	8.4M	6.3M	6.5M	4.2M	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	19.7M	13.3M	18.5M	4M	46.3M	24.7M	4.7M	8.5M	981K	369K	1M	0.0	0.0	0.0	0.0
Total Current Liabilities	36.4M	65.5M	82M	127M	99.5M	49.5M	21.3M	12.6M	11M	4.3M	2.4M	2.4M	1.6M	768K	219K
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	40.6M	13.8M	15M	9.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue (Non-Current)	0.0	12.6M	42.5M	20.1M	0.0	0.0	15.2M	7.5M	7.2M	3.4M	0.0	0.0	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	-4.9M	0.0	26.6M	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	0.0	0.0	497K	2.8M	19.9M	12.5M	0.0	8.1M	0.0	15K	0.0	0.0	0.0	0.0	0.0
Total Non-Current Liabilities	20.8M	37.6M	68.9M	53.1M	65.1M	30.4M	35M	18M	7.2M	3.4M	0.0	0.0	0.0	0.0	0.0
Other Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.4M	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations	20.8M	28.6M	30.2M	34.1M	6M	5.7M	4.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	57.2M	103.1M	150.9M	180.1M	164.6M	79.9M	56.4M	30.6M	18.2M	4.3M	2.4M	2.4M	1.6M	768K	219K
SHAREHOLDERS' EQUITY
Common Stock	28K	27K	27K	27K	26K	26K	15K	214K	212K	74K	74K	39K	39K	4K	4K
Additional Paid-In Capital	728.5M	689.8M	646.4M	608.4M	575.7M	540.3M	97.4M	58.3M	56.7M	13.8M	140.3M	71.5M	67.4M	7.6M	7.6M
Retained Earnings	-514.6M	-448.8M	-367.9M	-338.1M	-347.5M	-143.8M	-71.7M	-44.9M	-23.1M	-95.6M	-71M	-51.6M	-18.7M	-8.2M	-6.6M
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3K	-6K	-111K	-60K	-30K	-22K	-15K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-68K	0.0	0.0	0.0	13.8M	0.0
Total Stockholders' Equity	214M	241M	278.5M	270.3M	228.2M	396.6M	25.8M	13.6M	33.8M	47.2M	69.3M	19.9M	48.7M	-567K	985K
Total Equity	214M	241M	278.5M	270.3M	228.2M	396.6M	25.8M	13.6M	33.8M	47.2M	69.3M	19.9M	48.7M	-567K	985K
SUMMARY
Total Liabilities & Equity	271.1M	344.1M	429.4M	450.4M	392.8M	476.5M	82.1M	44.2M	52M	51.6M	71.7M	22.3M	50.3M	201K	1.2M
Total Investments	1.9M	0.0	1.9M	0.0	515K	0.0	263K	288K	23.6M	47.9M	53M	19.5M	28M	3K	517K
Total Debt	25M	28.6M	30.2M	94.8M	69.1M	20.8M	19.8M	9.9M	0.0	133K	0.0	0.0	0.0	662K	0.0
Net Debt	-205.9M	-208.5M	-261.8M	-297.1M	-301.3M	-442.1M	-51.5M	-26.8M	-25M	-2.2M	-16.7M	-2.2M	-22.1M	565K	-55K
Shares Outstanding	27,154,529	27,154,529	27,154,529	27,154,529	27,154,529	27,154,529	27,154,529	27,154,529	27,154,529	27,154,529	27,154,529	27,154,529	27,154,529	27,154,529	27,154,529

SEC Filings

ARCT - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 01, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 24, 2026	June 05, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 03, 2026	March 03, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 03, 2026	December 31, 2025	2025	View Filing
S-3 S-3 N/A	December 30, 2025	December 30, 2025		View Filing
8-K 8-K 2025 N/A	December 15, 2025	December 11, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 12, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 10, 2025	November 10, 2025	2025	View Filing
8-K 8-K 2025 N/A	October 22, 2025	October 22, 2025	2025	View Filing

Showing 1 to 10 of 144 filings

Related Guides

Blog Categories

Continue your ARCT research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.